Literature DB >> 16904053

Testosterone therapy for men at risk for or with history of prostate cancer.

Abraham Morgentaler1.   

Abstract

Since the early 1940s when Huggins showed that severe reductions in serum testosterone by castration or estrogen therapy caused regression of prostate cancer (PCa), it has been assumed that higher testosterone levels cause enhanced growth of PCa. For this reason, it has been considered taboo to offer testosterone replacement therapy (TRT) to any man with a prior history of PCa, even if all objective evidence suggests he has been cured. The fear has been that higher testosterone levels would "awaken" dormant cells and cause a recurrence. Thus, US Food and Drug Administration-mandated language in all testosterone package inserts states that testosterone is contraindicated in men with a history of, or suspected of having, PCa. Although there is little modern experience with administration of testosterone in men with known history of PCa, there is a varied and extensive literature indicating that TRT does not pose any increased risk of PCa growth in men with or without prior treatment. For instance, the cancer rate in TRT trials is only approximately 1%, similar to detection rates in screening programs, yet biopsy-detectable PCa is found in one of seven hypogonadal men. Moreover, PCa is almost never seen in the peak testosterone years of the early 20s, despite autopsy evidence that men in this age group already harbor microfoci of PCa in substantial numbers. The growing number of PCa survivors who happen to be hypogonadal and request treatment has spurred a change in attitude toward this topic, with increasing numbers of physicians now offering TRT to men who appear cured of their disease. Publications have now reported no prostate-specific antigen (PSA) recurrence with TRT in small numbers of men who had undetectable PSA values after radical prostatectomy. Although still controversial, there appears to be little reason to withhold TRT from men with favorable outcomes after definitive treatment for PCa. Monitoring with PSA and digital rectal examination at regular intervals is recommended.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16904053     DOI: 10.1007/s11864-006-0004-y

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  26 in total

1.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

Authors:  Charles Huggins; Clarence V Hodges
Journal:  J Urol       Date:  2002-07       Impact factor: 7.450

Review 2.  Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan.

Authors:  Shalender Bhasin; Atam B Singh; Ricky Phong Mac; Ballentine Carter; Martin I Lee; Glenn R Cunningham
Journal:  J Androl       Date:  2003 May-Jun

3.  Occult prostate cancer in men with low serum testosterone levels.

Authors:  A Morgentaler; C O Bruning; W C DeWolf
Journal:  JAMA       Date:  1996-12-18       Impact factor: 56.272

4.  Testosterone replacement therapy and the risk of prostate cancer: a perspective view.

Authors:  A B Barqawi; E D Crawford
Journal:  Int J Impot Res       Date:  2005 Sep-Oct       Impact factor: 2.896

5.  Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide).

Authors:  J M Kuhn; T Billebaud; H Navratil; A Moulonguet; J Fiet; P Grise; J F Louis; P Costa; J M Husson; R Dahan
Journal:  N Engl J Med       Date:  1989-08-17       Impact factor: 91.245

Review 6.  Is the flare phenomenon clinically significant?

Authors:  G J Bubley
Journal:  Urology       Date:  2001-08       Impact factor: 2.649

7.  The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.

Authors:  K Tomera; D Gleason; M Gittelman; W Moseley; N Zinner; M Murdoch; M Menon; M Campion; M B Garnick
Journal:  J Urol       Date:  2001-05       Impact factor: 7.450

8.  Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.

Authors:  Ernani Luis Rhoden; Abraham Morgentaler
Journal:  J Urol       Date:  2003-12       Impact factor: 7.450

Review 9.  Testosterone replacement therapy and prostate risks: where's the beef?

Authors:  Abraham Morgentaler
Journal:  Can J Urol       Date:  2006-02       Impact factor: 1.344

10.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

View more
  8 in total

1.  Low-risk prostate cancer and low testosterone: what are the acceptable alternatives?

Authors:  Mark Soloway
Journal:  Curr Urol Rep       Date:  2009-11       Impact factor: 3.092

2.  Clinically occult prostate cancer cases may distort the effect of testosterone replacement therapy on risk of PCa.

Authors:  Xiao Zhang; Yan Zhong; Farid Saad; Karim Haider; Ahmad Haider; Xiaohui Xu
Journal:  World J Urol       Date:  2019-01-18       Impact factor: 4.226

3.  Physiological normal levels of androgen inhibit proliferation of prostate cancer cells in vitro.

Authors:  Weitao Song; Mohit Khera
Journal:  Asian J Androl       Date:  2014 Nov-Dec       Impact factor: 3.285

4.  Episode-like pulse testosterone supplementation induces tumor senescence and growth arrest down-modulating androgen receptor through modulation of p-ERK1/2, pARser81 and CDK1 signaling: biological implications for men treated with testosterone replacement therapy.

Authors:  Giovanni Luca Gravina; Francesco Marampon; Patrizia Sanità; Claudio Festuccia; Chiara Forcella; Luca Scarsella; Anna Jitariuc; Antonella Vetuschi; Roberta Sferra; Alessandro Colapietro; Eleonora Carosa; Susanna Dolci; Andrea Lenzi; Emmanuele A Jannini
Journal:  Oncotarget       Date:  2017-11-30

5.  Testosterone inhibits the growth of prostate cancer xenografts in nude mice.

Authors:  Weitao Song; Vikram Soni; Samit Soni; Mohit Khera
Journal:  BMC Cancer       Date:  2017-09-07       Impact factor: 4.430

6.  MR-10 Enhances Men's Health by Improving Endogenous Male Sex Hormone Generation.

Authors:  Yoo-Hun Noh
Journal:  J Med Food       Date:  2018-09-04       Impact factor: 2.786

7.  Combined tests of prostate specific antigen and testosterone will improve diagnosis and monitoring the progression of prostate cancer.

Authors:  Weitao Song; Vikram Soni; Mohit Khera
Journal:  Asian J Androl       Date:  2015 Sep-Oct       Impact factor: 3.285

Review 8.  Risks of testosterone replacement therapy in men.

Authors:  E Charles Osterberg; Aaron M Bernie; Ranjith Ramasamy
Journal:  Indian J Urol       Date:  2014-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.